![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1592596
À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀå ¿¹Ãø(-2030³â) - Áö¿ªº° ºÐ¼® : Ç×ü À¯Çüº°, ¼ºÁúº°, ¼ºñ½ºº°, ÃÖÁ¾»ç¿ëÀÚº°Europe Antibody Discovery Market Forecast to 2030 - Regional Analysis - by Antibody Type, Nature, Services, and End User |
À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀåÀº 2022³â 8,244¾ï 4,111¸¸ ´Þ·¯·Î 2030³â±îÁö 1Á¶ 3,294¾ï 8,160¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 6.2%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾Ï ¹ßº´·ü Áõ°¡°¡ À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀåÀ» ÁÖµµ
2020³â¿¡ ¹ßÇ¥µÈ Global Cancer Observatory(GLOBOCAN)ÀÇ Ã߻꿡 µû¸£¸é, Àü ¼¼°èÀûÀ¸·Î 1,930¸¸ ¸íÀÇ ¾Ï ȯÀÚ°¡ ¹ß»ýÇßÀ¸¸ç, 2030³â 1¿ù±îÁö ¾Ï »ýÁ¸ÀÚ Àα¸´Â 2,210¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ÀÌ´Â ÁÖ·Î Àα¸ÀÇ °í·ÉÈ¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù. °í·ÉÈ¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù. Æó¾Ï, À¯¹æ¾Ï, ´ëÀå¾Ï, Àü¸³¼±¾Ï, À¯¹æ¾Ï µîÀÌ °¡Àå ¸¹ÀÌ º¸°íµÈ ¾Ï À¯ÇüÀÔ´Ï´Ù. ¾Ï ¹ßº´·üÀÇ Áõ°¡´Â Àü ¼¼°èÀûÀ¸·Î ¿ì·Á¸¦ ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.
¾ÏÀº ÇöÀç °Ç°¿¡ ÁÁÁö ¾ÊÀº ½Ä½À°ü°ú ¿îµ¿ ºÎÁ·À» °¡Áø »ç¶÷µé¿¡°Ô¼ ÈçÈ÷ º¼ ¼ö ÀÖ´Â »ýȰ½À°üº´ÀÔ´Ï´Ù. ¼ú°ú ´ã¹è¸¦ ÀÚÁÖ ¼·ÃëÇÏ¸é ¾Ï ¹ß»ý À§ÇèÀÌ ³ô¾ÆÁý´Ï´Ù. ÁßÀú¼Òµæ ±¹°¡ÀÇ ¸¸¼º °¨¿°Àº ¾ÏÀÇ À§Çè ¿äÀÎÀ» ´õ¿í ¾ÇȽÃŵ´Ï´Ù. ¾Ï ¹ßº´·üÀÇ Áõ°¡´Â Çõ½ÅÀûÀÎ ¾Ï Ä¡·áÁ¦ÀÇ Çʿ伺À» º¸¿©ÁÝ´Ï´Ù. ´ÜŬ·ÐÇ×ü´Â ¾Ï¼¼Æ÷ÀÇ È°µ¿À» ¾ïÁ¦ÇÏ°í ¸é¿ªÃ¼°èÀÇ ÀÚ¿¬Àû ¾Ï¼¼Æ÷ Á¦°Å ´É·ÂÀ» Çâ»ó½ÃŰ´Â À¯¸ÁÇÑ Ç¥ÀûÇ×¾ÏÁ¦ÀÔ´Ï´Ù. Ç×ü¾à¹°Á¢ÇÕü(ADC)µµ ¾Ï Ä¡·á¿¡¼ À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Çö´ë »ý¸í°øÇÐÀÇ ¹ßÀüÀ¸·Î ¿¬±¸ÀÚµé°ú ±â¾÷µéÀº ´Ù¾çÇÑ Á¾·ùÀÇ ¾ÏÀ» ¼º°øÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â ¿ì¼öÇÑ µðÀÚÀÎÀÇ »õ·Î¿î Ç×ü¸¦ Á¦°øÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌó·³ ´Ù¾çÇÑ À¯ÇüÀÇ ¾ÏÀÌ ±ÞÁõÇÏ¸é¼ Ç×ü Ž»ö ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀå °³¿ä
À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ªÀº ¼¼°è ½ÃÀå¿¡¼ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸ °³¹ß, ¾Ï Ä¡·á, ¸é¿ª Áúȯ °ü¸®¿¡¼ ´ÜŬ·ÐÇ×üÀÇ »ç¿ëÀÌ ±ÞÁõÇÔ¿¡ µû¶ó ÇâÈÄ ¸î ³â µ¿¾È °ß°íÇÑ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ȯÀÚ µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸¸¼ºÁúȯÀÇ À¯Çà, Ç×ü ¼ºñ½º µµÀÔ¿¡ ´ëÇÑ Á¤ºÎÀÇ ³ë·Â µîÀº ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ µîÀÇ ±¹°¡¿¡¼ Ç×ü Ž»ö ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(10¾ï ´Þ·¯)
À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀå ¼¼ºÐÈ
À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀåÀº Ç×ü À¯Çü, Ư¼º, ¼ºñ½º, ÃÖÁ¾»ç¿ëÀÚ ¹× ±¹°¡·Î ºÐ·ùµË´Ï´Ù.
Ç×ü À¯Çü¿¡ µû¶ó À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀåÀº ´ÜŬ·ÐÇ×ü, ´ÙŬ·ÐÇ×ü, ±âŸ·Î ±¸ºÐµË´Ï´Ù. ´ÜŬ·ÐÇ×ü ºÎ¹®Àº 2022³â À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¼ºÁúº°·Î À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀåÀº Àΰ£ ¹× Àΰ£È, Ű¸Þ¶ó, ¸¶¿ì½º·Î ±¸ºÐµË´Ï´Ù. Àΰ£ ¹× Àΰ£È ºÎ¹®Àº 2022³â À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¼ºñ½ºº°·Î À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀåÀº ÆÄÁö µð½ºÇ÷¹ÀÌ, ÇÏÀ̺긮µµ¸¶, ÇüÁúÀüȯ µ¿¹°, ´ÜÀÏ ¼¼Æ÷, È¿¸ð µð½ºÇ÷¹ÀÌ·Î ³ª´¹´Ï´Ù. ÆÄÁö µð½ºÇ÷¹ÀÌ ºÎ¹®Àº 2022³â À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚº°·Î À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀåÀº Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷, ¿¬±¸¼Ò, ±âŸ·Î ºÐ·ùµË´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ ºÎ¹®Àº 2022³â À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ºÐ·ùµÇ¸ç, 2022³â À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀå Á¡À¯À²Àº µ¶ÀÏÀÌ µ¶Â÷ÁöÇß½À´Ï´Ù.
Charles River Laboratories International Inc, Creative Biolabs Inc, Evotec SE, Sartorius AG, Aragen Life Sciences Ltd, Twist Bioscience Corp, Biocytogen Pharmaceuticals Beijing Co Ltd.´Â À¯·´ÀÇ Ç×ü Ž»ö ½ÃÀå¿¡¼ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.
The Europe antibody discovery market was valued at US$ 8,24,441.11 million in 2022 and is expected to reach US$ 13,29,481.60 million by 2030; it is estimated to register a CAGR of 6.2% from 2022 to 2030.
Rising Incidence of Cancer Drives Europe Antibody Discovery Market
As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the world. By January 2030, the population of cancer survivors is estimated to reach 22.1 million, which can be primarily associated with the aging of the population. Lung, breast, colorectal, prostate, and breast are among the most commonly reported cancer types. The rising incidences of cancer have raised concerns worldwide.
Cancer is now a lifestyle disease commonly seen among people with unhealthy eating habits and those who don't engage much in physical activities. The frequent consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. An upsurge in the incidence of cancer indicates the need for innovative cancer treatments. Monoclonal antibodies represent a promising class of targeted anticancer agents that enhance the natural ability of immune systems to suppress cancer cell activity and eliminate cancer cells. Antibody-drug conjugates (ADCs) have also shown promising results in cancer treatment. Further, progress in modern biotechnology allows researchers and companies to provide well-designed novel antibodies, paving the way for successful treatments of various types of cancer. Thus, the burgeoning incidence of different types of cancer boosts the antibody discovery market growth.
Europe Antibody Discovery Market Overview
The European antibody discovery market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global market. It is expected to register a robust growth rate in the coming years owing to the surging use of monoclonal antibodies in R&D applications, cancer therapies, and immunological disorder management. Further, the rising need for patient data management systems, the prevalence of chronic diseases, and government initiatives for the implementation of antibody services are expected to provide growth opportunities for the antibody discovery market in countries such as France, Italy, and Spain.
Europe Antibody Discovery Market Revenue and Forecast to 2030 (US$ Billion)
Europe Antibody Discovery Market Segmentation
The Europe antibody discovery market is categorized into antibody type, nature, services, end user, and country.
Based on antibody type, the Europe antibody discovery market is segmented into monoclonal antibodies, polyclonal antibodies, and others. The monoclonal antibodies segment held the largest Europe antibody discovery market share in 2022.
In terms of nature, the Europe antibody discovery market is segmented into human and humanized, chimeric, and murine. The human and humanized segment held the largest Europe antibody discovery market share in 2022.
By services, the Europe antibody discovery market is divided into phage display, hybridoma, transgenic animal, single cell, and yeast display. The phage display segment held the largest Europe antibody discovery market share in 2022.
Based on end user, the Europe antibody discovery market is categorized into pharmaceutical and biotechnology companies, research laboratories, and others. The pharmaceutical and biotechnology companies segment held the largest Europe antibody discovery market share in 2022.
Based on country, the Europe antibody discovery market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe antibody discovery market share in 2022.
Charles River Laboratories International Inc, Creative Biolabs Inc, Evotec SE, Sartorius AG, Aragen Life Sciences Ltd, Twist Bioscience Corp, and Biocytogen Pharmaceuticals Beijing Co Ltd. are some of the leading companies operating in the Europe antibody discovery market.